Brief: Calidi Biotherapeutics Announces FDA Clearance Of Northwestern University's IND Application For CLD-101 Clinical Trial
30/09/2024 13:30
Sept 30 (Reuters) - Calidi Biotherapeutics Inc CLDI.A :
* CALIDI BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE OF THE
NORTHWESTERN UNIVERSITY IND APPLICATION FOR CLD-101 CLINICAL
TRIAL IN HIGH-GRADE GLIOMA
* CALIDI BIOTHERAPEUTICS INC - PHASE 1B/2 TRIAL TO COMMENCE
IN
LATE 2024
* CALIDI BIOTHERAPEUTICS INC - PHASE 1B/2 STUDY TO EVALUATE
SAFETY
AND FEASIBILITY OF CLD-101
Source text for Eikon: urn:newsml:reuters.com:*:nGNX2Sk764
Further company coverage: CLDI.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma